@article{44b1de7577644e5a86cc3489fe2abc5f,
title = "Examination of voluntary compliance with new fda cigar warning label requirements",
abstract = "Objectives: The US Food and Drug Administration (FDA) issued new requirements to strengthen and increase the size of cigar warnings. Although these requirements were challenged in court by the cigar industry, and later struck down, cigar manufacturers had the option of voluntarily complying during the injunction. In this study, we examined voluntary warning compliance on a sample of discarded cigar wrappers. Methods: Warnings were examined on a sample of 1352 discarded cigar wrappers and packs obtained from 15 census tracts in Oakland, California in February 2019. Warnings were coded for new requirement compliance (ie, sized at 30% or more on front and back of pack). Results: Overall, 67.3% of wrappers displayed compliant warnings – other wrappers had smaller warnings only on the front (30.6%), only on the back (1.5%) or no warning (0.4%). Cigar warning placement was significantly associated with brand (p < .01), cigar type (p < .01), and unit size (p < .01). The prevalence of warning compliance was at least 90% for 6 brands but ranged from 0% to 65% for others. Compliance was lowest for cigarillos (62.1%) and packs of 3 (27.6%). Conclusions: Strengthening cigar warnings can help increase their effectiveness, but cigar manufacturers may not voluntarily implement changes fully. Continued surveillance and renewed regulatory efforts are warranted.",
keywords = "Cigarillos, Cigars, Tobacco policy, Warning labels",
author = "Wackowski, {Olivia A.} and Marin Kurti and Schroth, {Kevin R.J.} and Delnevo, {Cristine D.}",
note = "Funding Information: Research reported in this publication was supported by a grant from the Rutgers Cancer Institute of New Jersey (P30CA072720), and efforts by OAW, MK, KRJS and CDD were also supported by the NCI and FDA Center for Tobacco Products (CTP) under Award Number U54CA229973. The content is solely the responsibility of the authors and does not necessarily represent the official views of the funders, including CINJ, NIH or the Food and Drug Administration. Funding Information: Research reported in this publication was supported by a grant from the Rutgers Cancer Institute of New Jersey (P30CA072720), and efforts by OAW, MK, KRJS and CDD were also supported by the NCI and FDA Center for Tobacco Products (CTP) under Award Number U54CA229973. The content is solely the responsibility of the authors and does not necessarily represent the official views of the funders, including CINJ, NIH or the Food and Drug Administration. OAW led writing of the paper and contributed to development of the coding instrument and data analysis plan. KRJS and MK obtained funding for data collection. MK developed the coding instrument, led data collection and analysis and participated in manuscript writing and editing. KRJS and CDD contributed to the study design and instrument and contributed to manuscript writing and editing. We thank Christopher Ackerman for his many efforts on this project and our entire data collection team including Michelle Jeong, Michelle Kennedy, Binu Singh, and Eugene Talbot. Publisher Copyright: {\textcopyright} 2020, Tobacco Regulatory Science Group. All rights reserved.",
year = "2020",
month = nov,
doi = "10.18001/TRS.6.6.1",
language = "English (US)",
volume = "6",
pages = "379--383",
journal = "Tobacco Regulatory Science",
issn = "2333-9748",
publisher = "Tobacco Regulatory Science Group",
number = "6",
}